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Objective: The objective of this study was to estimate the economic impact of the introduction 
of DuoResp® Spiromax®, budesonide/formoterol fixed-dose combination (FDC), focusing on 
an increase in medication adherence due to an enhancement of the inhalation technique for the 
treatment of COPD patients in Spain and 5 regions including Andalusia, Catalonia, Galicia, 
Madrid, and Valencia.
Methods: A 4-year budget impact model was developed for the time period of 2015–2018. 
This study aimed at evaluating the budget impact associated with the introduction of DuoResp 
Spiromax in comparison with Symbicort® Turbuhaler® and Rilast® Turbuhaler. National and 
regional data on COPD prevalence were obtained from the literature. Input data on health care 
resource utilization were obtained by clinical consultation. Resource included primary care visits, 
specialist visits, hospitalization, and emergency room visits as well as the length of hospital 
stay. Based on both pharmacological and health care resource costs, overall annual treatment 
cost per patient was estimated in EUR 2015. 
Results: It was calculated that 130,777 adults were treated with budesonide/formoterol FDC 
delivered by a dry powder inhaler, Turbuhaler, in Spain in 2015. However, the target population 
decreases over the next 4 years. This pattern was observed in 4 regions, but for Andalusia, the 
treated population increased slightly. The overall budget savings in Spain with the market share of 
DuoResp Spiromax were estimated to be €6.01 million for the time period of 2015–2018. Region-
specific data resulted in savings of €902,133 in Andalusia, €740,520 in Catalonia, €464,281 
in Galicia, €748,996 in Madrid, and €495,812 in Valencia for the time period of 2015–2018. 
Conclusion: The introduction of budesonide/formoterol FDC delivered by Spiromax for COPD 
treatment is likely to contribute in a reduction of health care costs for Spain and in 5 Spanish regions. 
This model forecasts that Spain and these 5 Spanish regions were likely to have savings, which 
might be due to fewer days of hospitalization, avoided emergency room, and primary care visits.
Keywords: dry powder inhaler, economic evaluation, region-specific estimates, payers’ 
perspective
Introduction
COPD is characterized by persistent airflow limitation related to a chronic inflam-
matory response in the airways and the lung derived from inhaling toxic particles or 
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gases for a long-term exposure.1 This condition is the fourth 
leading cause of death worldwide, and it represents a major 
cause of chronic morbidity and economic and social burden.1 
Thus, some studies have focused on calculating the cost of 
treatment for COPD in Spain. de Miguel Diez et al2 showed 
that the total treatment cost per COPD patient per year was 
~€2,000. In that study, 40% of the total expenses were pro-
duced by the hospitalization component, and the drug costs 
represented almost the 26%. Masa et al3 also conducted a 
study on the COPD treatment costs in Spain and found that 
although the cost per patient was not calculated, the divi-
sion of expenses was similar to the one obtained by Miguel 
Diez et al, corresponding 41% to hospitalization and 37% 
to pharmacological treatment.
In Spain, 10.2% of individuals between the ages of 40 
and 80 years have COPD, whereas a significant proportion of 
the population remains undiagnosed.4 This high prevalence 
is worsened by the fact that ~60% of patients with COPD 
do not adhere to the prescribed therapy.5,6
Medication adherence is a complex issue that can be defined 
as the degree to which a patient’s medication-taking behavior 
and/or executing lifestyle changes correspond with agreed 
recommendations from a health care professional with respect 
to timing, dosage, and frequency.7 Medication adherence is a 
key factor for controlling the progression of chronic disease. 
Although inhaled corticosteroids (ICS) and long-acting 
β2-agonist  fixed-dose combinations (FDCs) have shown 
to relieve COPD symptoms similarly, inhalation technique 
might affect adherence and hence efficacy of pharmacologi-
cal treatment. Common, real-life errors during the inhalation 
process include holding inhaler upright, inhaling deeply and 
quickly, and breath-holding.8,9 Delivering sufficient drug dose 
to the lungs is crucial to achieve a good medication efficacy 
so as to avoid poor health outcomes.10 
As in other chronic diseases, the previous studies have 
demonstrated low medication adherence in COPD patients. A 
study distributed by the World Health Organization reported 
that in patients on long-term pharmacotherapy the adherence 
was half or less.11 Recent studies, based on the medication 
adherence in COPD patients, additionally show a poor adher-
ence. Breekveldt-Postma et al12 reported that approximately 
half of the patients stopped their treatment with ICS within 
6 months, and only 18% persevered >1 year. Bender et al13 
studied the utilization of an inhaler (fluticasone propionate/
salmeterol) and detected that only 9% of patients proceed 
with the treatment for more than 1 year. Cramer et al14 identi-
fied that the adherence to COPD medications was low over 
a wide range of medications, ranging from 57 to 96 mean 
days until discontinuation over a year of observation time.
Medication regimens for patients with COPD are nota-
bly susceptible to adherence problems due to the chronicity 
of the disease, the use of multiple medications, and the 
periods of symptom remission and patients’ comorbidities. 
Given the developments in inhaler devices (eg, pressurized 
metered-dose inhalers to dry powder inhalers [DPIs]), there 
is still a high unmet need to have more intuitive inhalers that 
are easier to use for patients. This is also recognized by the 
decision makers and physicians.15,16 The ease of use of the 
device according to patient comorbidities and preferences 
may contribute to a better medication adherence.7 
The present study focused on developing a budget impact 
model (BIM) in order to estimate the economic impact that 
arises from a growing presence in the market of DuoResp® 
Spiromax® for the maintenance therapy with budesonide/
formoterol FDC. Spiromax, a new inhalation device, helps 
to reduce common errors that could occur while using the 
device which could limit the direct drug delivery to the 
lungs.17 The model was elaborated from the perspective of 
the Spanish National Honor Society (NHS), and regional data 
from 5 Spanish autonomous communities (hereafter referred 
as regions) were also included: Andalusia, Catalonia, Galicia, 
Madrid, and Valencia. 
Methods
Model development and structure
This study did not require any ethics committee review as the 
authors did not have access to patient-level data. The BIM 
was developed in Microsoft Excel from the perspective of the 
Spanish NHS with a 4-year time horizon (2015–2018). The 
present analysis focused on the population from Spain and 5 
Spanish regions: Andalusia, Catalonia, Galicia, Madrid, and 
Valencia. Budesonide/formoterol FDC delivered by Turbu-
haler was considered the relevant comparator for evaluating 
the budget impact of the introduction of budesonide/for-
moterol FDC delivered by Spiromax. Although FDCs such 
as beclomethasone/formoterol and fluticasone/salmeterol are 
available, only budesonide/formoterol FDC was included in 
the present analysis because changes in patients’ regimens 
were not hypothesized. 
Input data on health care resources such as medical visits 
and length of hospitalization were obtained by expert panel 
consultation from various Spanish hospitals. Therefore, the 
model analyzed health care resource utilization per patient 
based on his/her daily maintenance treatment for COPD and 
the number of days with events such as hospitalizations, 
visits to the emergency room, primary care (PC) visits, and 
specialist visits. These data were obtained from daily clinical 
practice, given that there is no published literature on how 
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suboptimal adherence related to inhalation technique affects 
health care resource utilization. 
All the costs were estimated in EUR 2015, and a discount 
rate of 3% was assumed. It should be noted that when this 
study was being completed, there was a significant change 
in drug prices included in this analysis. From October 2015 
onward, prices of both the drugs were set at the same level 
by the Spanish Ministry of Health; therefore, price effect 
was no longer useful to calculate the economic impact of 
the introduction of DuoResp Spiromax.18
The model focused on diagnosed patients with COPD, 
who followed an inhaler maintenance therapy. IMS Health 
reported the proportion of patients using budesonide/
formoterol FDC delivered by a DPI according to Spanish 
national and regional sales data. Therefore, the authors were 
able to estimate the target population, given the data on Sym-
bicort/Rilast Turbuhaler utilization in Spain and 5 Spanish 
regions. Data on market uptake of DuoResp Spiromax were 
provided directly by Teva Pharma, Spain. 
The model provided estimates for the annual costs per 
patient and the total direct costs of treatment from predefined 
market shares and other input parameters. The total cost 
estimated for COPD patients is based on drug costs and 
medical resources, such as medical visits, hospitalization, 
emergency visits, and monitoring tests. It was assumed that 
all the patients received treatment during a whole year.
Sensitivity analysis
A univariate deterministic sensitivity analysis was conducted 
to confirm the model robustness and to identify the param-
eters having the greatest influence on the results. Different 
market shares, adherence rates, and COPD severity were 
assessed for the analysis. Furthermore, a change in the age of 
the target population was analyzed, considering the popula-
tion older than 40 years (greater COPD prevalence) instead 
of the adult population.
Model input variables
Target population
The study population analysis was conducted by applying 
the algorithm defined in Figure 1. The study population was 
selected based on Spanish national and regional prevalence 
of COPD from the literature review.19,20 Prevalence estimates 
of COPD were extrapolated to the obtained estimates of adult 
population, taking into account projections performed by 
the Spanish National Institute of Statistics.21 We considered 
that 73% of COPD patients were not diagnosed.22 Finally, 
a percentage was applied to distinguish the patients using 
an FDC, and among them, the number of patients who 
used budesonide/formoterol FDC delivered by a DPI was 
determined. The proxy for capturing these patients was the 
percentage of patients using Symbicort/Rilast Turbuhaler 
(IMS Health. National sales data 2013-2014 for COPD 
maintenance treatment with fixed-dose-combinations for 
Spain, unpublished data, 2015).
Adherence, medical resource utilization, 
and costs
A panel of 5 clinical experts in pneumology and allergy and 
also a general practitioner from different Spanish hospitals 
was asked to report whether critical inhaler misuses were 
observed in daily practice. The incorrect dose loading and 
keeping the inhaler inclined no more than 45° from the ver-
tical axis were the most common errors in patients taking 
Symbicort Turbuhaler and Rilast Turbuhaler versus DuoResp 
Spiromax (Table 1). These results were not used for calcula-
tions, but these were relevant to confirm that the misuse of 
inhaler was found in clinical practice. 
Gathering input data on health care resource utilization 
related to a potential enhancement of adherence was the basis 
to estimate the economic impact of the introduction of Spi-
romax in Spain. The expert panel also provided estimates for 
health care resource utilization. The proportion of emergency 
room visits and hospitalizations that might be due to errors 
in the use of inhaler technique were reported to be 4.92% 
and 3.26%, respectively. Moreover, according to the experts’ 
Total adult population
>18 years
COPD prevalence
Percentage of diagnosed
patients who are treated
with an FDC
Region-specific percentage
of patients who are treated
with Rilast/Symbicort
Turbuhaler
Adult population with COPD in
Spain
Adult population with diagnosed
COPD who receives FDC therapy
Target population that receives
budesonide/formoterol FDC
delivered by DPI
Figure 1 Target population of the study.
Notes: COPD prevalence: in Spain 10.20%, in Andalusia 10.13%, in Catalonia 
11.90%, in Galicia 8.20%, in Madrid 11.00%, and in Valencia 7.61%; region-specific 
percentage of patients who are treated with Rilast®/Symbicort® Turbuhaler®: in 
Spain 34.99%, in Andalusia 33.85%, in Catalonia 31.53%, in Galicia 34.97%, in Madrid 
36.46%, and in Valencia 34.26%; percentage of patients who are treated with a fixed-
dose combination (FDC): in Spain 35.85%, in Andalusia 31.23%, in Catalonia 33.42%, 
in Galicia 42.86%, in Madrid 38.17%, and in Valencia 31.64%.
Abbreviations: DPI, dry powder inhaler; FDC, fixed-dose combination.
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Table 1 Errors observed in daily practice
Checklist of inhalation 
technique errors
Patients using 
Symbicort®/
Rilast® 
Turbuhaler® 
(%)
Patients 
using 
DuoResp® 
Spiromax® 
(%)
Failure of loading 17.17 0.83
No breath-holding after inhalation 37.00 36.67
Keep the inhaler inclined no more 
than 45° from the vertical axis 
during loading
22.33 5.83
No exhalation prior to inhalation 35.83 28.67
Stop inhaling prematurely 27.67 22.50
Exhaling into the device mouthpiece 
after inhalation
12.17 8.83
Notes: These percentages were not used for calculation. Sources: Clinical expert 
panel of pneumologists, allergists, and a general practitioner.
point of view, there are some differences in the number of 
emergency room visits and hospitalizations between patients 
using Turbuhaler and patients using Spiromax (Table 2). 
There were some difficulties in obtaining directly the pro-
portions of PC visits and specialist visits per patient. PC visits 
implies that the health care providers need to deal with different 
patient concerns, which might not be related only to the use of 
inhaler devices. Such situations made it necessary to ask for the 
number of PC and specialist visits that a regular COPD patient 
had undergone. On average, the number of patients who used 
Table 2 Drug cost, medical resource utilization, unit costs, and average cost per patient per year in EUR (€) 2015
Symbicort®  
Turbuhaler®
Rilast®  
Turbuhaler®
DuoResp® 
Spiromax®
Mean of regional unit 
costs in € 2015a
Annual resources:
Medical visits
PC 6.80 6.80 5.80 52.62
Specialist physician 2.40 2.40 2.40 75.15
Emergency room visits 0.016 0.016 0.009 173.31
Hospital resource utilization
Number of hospitalizationsb 0.010 0.010 0.010 492.39
Length of hospital stay 7.60 7.60 6.60 –
Other interventions 
Spirometry 0.17 0.17 0.17 31.69
Thorax radiography 0.40 0.40 0.40 20.98
Annual drug and medical resources costs per patient:
Drug cost of budesonide/formoterol FDC (€)c 240 240 231 –
Cost of medical visits (€) 541 541 487 –
Cost of hospital resource utilization (€)b 37 37 32 –
Cost of other interventions (€) 14 14 14 –
Cost per patient (€) 832 832 764 –
Notes: aMean of unit costs of 12 Spanish regions. Region-specific unit costs of health care resources were used to estimate the economic impact in the 5 regions included. 
bThe proportions of patients who visited the emergency room and those who are hospitalized due to suboptimal inhaler utilization were 4.92% and 3.26%, respectively. 
Among patients who visited the emergency room, it was observed that on average the number of events, such as hospitalizations, visits to the emergency room, primary care 
(PC) visits, and specialist visits, with Turbuhaler were 0.33 and with Spiromax were 0.27, which result in 0.016 times €173.71. The authors performed the same calculations 
with number of hospitalizations, which resulted in 0.010 times €492.39. cDifferences in drug cost were due to the differences in distributions of doses. However, drug cost 
was not associated with adherence; therefore, this variation was offset for the calculation of adherence effect. Sources: Clinical expert panel of pneumologists, allergists, and 
a general practitioner.
Abbreviations: DPI, dry powder inhaler; FDC, fixed-dose combination; PC, primary care.
Turbuhaler should not be different from those using Spiromax 
as they share indication with the same FDC of budesonide/
formoterol.23 Therefore, it is plausible to imply that deviation 
between health care resource utilization associated with Spiro-
max versus Turbuhaler might be related to the inhalation device.
Finally, the present study included other health care 
resources such as spirometry and thorax radiograph.3 Some 
studies showed that a greater number of monitoring tests such 
as blood test and electrocardiogram were taken, causing the 
budget to exceed the cost of a regular monitoring test, which 
are most efficient to make a prognostic of COPD.24 Therefore, 
it can be concluded that the cost of monitoring tests could be 
underestimated in the present model. 
Drug costs were obtained from a Spanish Database of 
Pharmacists.25 Cost of budesonide/formoterol FDC delivered 
by Turbuhaler or Spiromax was included exclusively as a drug 
cost in order to simplify the analysis. Costs of health care 
resources included in this analysis were based on Spanish 
regional tariff lists.26–37 At the national level, costs of health 
care resources correspond to the mean of 12 regions, includ-
ing those 5 regions included in this analysis.
Budgetary impact analysis
For each scenario, the economic impact for the time period 
of 2015–2018 was calculated based on the estimated number 
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of patients who are treated with budesonide/formoterol FDC 
delivered by Turbuhaler each year, the annual average cost per 
patient for each treatment option, the target population, and 
the market shares for both products included in this study. 
In the current scenario, DuoResp Spiromax was not com-
mercialized in the market (0% market share). This current 
scenario was compared with an alternative scenario in which 
the economic impact considered the introduction of DuoResp 
Spiromax and its effects toward medication adherence. The 
market uptake of DuoResp Spiromax increased gradually 
over the course of the 4 years (Table 3).
Table 3 Distribution of treatments (year [%]): base case analysis 
and alternative scenario
2015 (%) 2016 (%) 2017 (%) 2018 (%)
Base case analysis
Symbicort® 
Turbuhaler®
50.00 50.00 50.00 50.00
Rilast® Turbuhaler® 50.00 50.00 50.00 50.00
DuoResp® 
Spiromax®
0 0 0 0
Alternative scenario
Symbicort 
Turbuhaler
44.50 41.00 39.00 37.50
Rilast Turbuhaler 44.50 41.00 39.00 37.50
DuoResp Spiromax 11.00 18.00 22.00 25.00
Note: Data provided courtesy of Teva Pharma, Spain. 
Table 4 Target population for COPD treatment
Target population (n) Year
2015 2016 2017 2018
Spain
Adult patients with COPD 3,861,722 3,839,410 3,817,682 3,798,002
Adult patients diagnosed and treated with an FDC 373,798 371,634 369,531 367,626
Adult patients treated with budesonide/formoterol delivered by a DPI 130,777 130,020 129,284 128,618
Andalusia
Adult patients with COPD 683,721 683,930 684,130 684,515
Adult patients diagnosed and treated with an FDC 57,648 57,666 57,683 57,715
Adult patients treated with budesonide/formoterol delivered by a DPI 19,514 19,520 19,526 19,537
Catalonia
Adult patients with COPD 703,566 694,779 686,440 678,818
Adult patients diagnosed and treated with an FDC 63,483 62,690 61,938 61,250
Adult patients treated with budesonide/formoterol delivered by a DPI 20,016 19,766 19,529 19,312
Galicia
Adult patients with COPD 192,217 191,148 190,090 189,073
Adult patients diagnosed and treated with an FDC 22,242 22,119 21,996 21,879
Adult patients treated with budesonide/formoterol delivered by a DPI 7,778 7,734 7,692 7,650
Madrid
Adult patients with COPD 566,610 562,572 558,661 555,121
Adult patients diagnosed and treated with an FDC 58,392 57,976 57,573 57,208
Adult patients treated with budesonide/formoterol delivered by a DPI 21,289 21,138 20,991 20,858
Valencia
Adult patients with COPD 305,243 302,566 299,975 297,573
Adult patients diagnosed and treated with an FDC 26,080 25,851 25,630 25,424
Adult patients treated with budesonide/formoterol delivered by a DPI 8,936 8,858 8,782 8,712
Abbreviations: DPI, dry powder inhaler; FDC, fixed-dose combination.
Results
It was estimated that, in 2015, 130,777 adults in Spain suf-
fered from COPD, and they were treated with budesonide/
formoterol delivered by a DPI (in this study Turbuhaler; 
Table 4). However, this population decreased over time and 
will be 128,618 in 2018. This decrement responded to the 
demographic change in the general population. The same 
pattern was observed for target population in Catalonia, Gali-
cia, Madrid, and Valencia, whereas the number of patients in 
Andalusia increased slightly between 2015 and 2018 (Table 4).
Based on the annual drug cost and health care resource 
use per patient, the total treatment cost per patient was 
estimated in EUR 2015. With the annual average cost per 
patient for each treatment option, the target population, and 
the market shares for both products included in this study, the 
overall economic impact of the management of COPD for the 
time period of 2015–2018 was obtained. In the current sce-
nario for Spain, the total economic impact of treatment with 
budesonide/formoterol FDC delivered by Turbuhaler was 
estimated to be €108.76 million, €110.44 million, €114.61 
million, and €121.73 million for the years 2015, 2016, 2017, 
and 2018, respectively (Table 5). In the alternative scenario 
for Spain, with the market share of DuoResp Spiromax 
increasing annually from 2015, matched by a reduction in 
the share of Symbicort Turbuhaler and Rilast Turbuhaler, the 
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Table 5 Results of the base case budget impact analysis in EUR 2015 (€)
Year
2015 2016 2017 2018 Present value
Spain Current scenario
Symbicort® Turbuhaler® 54,382,762 55,221,607 57,307,803 60,867,158 217,716,147
Rilast® Turbuhaler® 54,382,762 55,221,607 57,307,803 60,867,158 217,716,147
Total cost 108,765,525 110,443,214 114,615,607 121,734,316 435,432,295
Alternative scenario
Symbicort Turbuhaler 48,400,658 45,281,717 44,700,087 45,650,368 176,274,165
Rilast Turbuhaler 48,400,658 45,281,717 44,700,087 45,650,368 176,274,165
DuoResp® Spiromax® 11,118,937 18,463,363 23,389,224 28,177,600 76,877,616
Total cost 107,920,255 109,026,799 112,789,398 119,478,338 429,425,947
Budget impact savings
−845,270 −1,416,415 −1,826,209 −2,255,979  −6,006,348
Andalusia Current scenario
Symbicort Turbuhaler 8,106,166 8,281,603 8,645,751 9,235,267 32,747,585
Rilast Turbuhaler 8,106,166 8,281,603 8,645,751 9,235,267 32,747,585
Total cost 16,212,332 16,563,206 17,291,503 18,470,535 65,495,171
Alternative scenario
Symbicort Turbuhaler 7,214,488 6,790,914 6,743,686 6,926,450 26,502,863
Rilast Turbuhaler 7,214,488 6,790,914 6,743,686 6,926,450 26,502,863
DuoResp Spiromax 1,657,789 2,769,674 3,529,544 4,276,478 11,587,311
Total cost 16,086,765 16,351,502 17,016,917 18,129,380 64,593,038
Budget impact savings
−125,567 −211,703 −274,586 −341,155 −902,133
Catalonia Current scenario
Symbicort Turbuhaler 7,036,367 7,085,759 7,284,274 7,656,351 27,788,519
Rilast Turbuhaler 7,036,367 7,085,759 7,284,274 7,656,351 27,788,519
Total cost 14,072,734 14,171,518 14,568,549 15,312,703 55,577,039
Alternative scenario
Symbicort Turbuhaler 6,262,367 5,810,322 5,681,734 5,742,263 22,514,021
Rilast Turbuhaler 6,262,367 5,810,322 5,681,734 5,742,263 22,514,021
DuoResp Spiromax 1,442,542 2,375,347 2,980,215 3,552,053 9,808,476
Total cost 13,967,276 13,995,992 14,343,684 15,036,581 54,836,519
Budget impact savings
−105,459 −175,526 −224,865 −276,122  −740,520
Galicia Current scenario
Symbicort Turbuhaler 3,790,274 3,854,414 4,010,272 4,273,525 15,223,372
Rilast Turbuhaler 3,790,274 3,854,414 4,010,272 4,273,525 15,223,372
Total cost 7,580,548 7,708,829 8,020,545 8,547,050 30,446,745
Alternative scenario
Symbicort Turbuhaler 3,373,344 3,160,620 3,128,012 3,205,144 12,323,520
Rilast Turbuhaler 3,373,344 3,160,620 3,128,012 3,205,144 12,323,520
DuoResp Spiromax 768,535 1,278,100 1,623,336 1,962,387 5,335,423
Total cost 7,515,223 7,599,340 7,879,362 8,372,675 29,982,463
Budget impact savings
−65,324 −109,489 −141,184 −174,375 −464,281
Madrid Current scenario
Symbicort Turbuhaler 7,940,250 8,044,041 8,321,122 8,802,898 31,649,353
Rilast Turbuhaler 7,940,250 8,044,041 8,321,122 8,802,898 31,649,353
Total cost 15,880,500 16,088,082 16,642,244 17,605,796 63,298,706
Alternative scenario
Symbicort Turbuhaler 7,066,822 6,596,113 6,490,475 6,602,173 25,630,636
Rilast Turbuhaler 7,066,822 6,596,113 6,490,475 6,602,173 25,630,636
DuoResp Spiromax 1,641,197 2,719,043 3,433,623 4,120,535 11,288,438
Total cost 15,774,843 15,911,270 16,414,574 17,324,882 62,549,711
Budget impact savings
−105,657 −176,812 −227,670 −280,914  −748,996
Valencia Current scenario
Symbicort Turbuhaler 4,123,785 4,178,338 4,330,637 4,597,319 16,469,664
Rilast Turbuhaler 4,123,785 4,178,338 4,330,637 4,597,319 16,469,664
Total cost 8,247,571 8,356,675 8,661,274 9,194,639 32,939,328
Alternative scenario
Symbicort Turbuhaler 3,670,169 3,426,237 3,377,897 3,447,989 13,336,004
Rilast Turbuhaler 3,670,169 3,426,237 3,377,897 3,447,989 13,336,004
DuoResp Spiromax 837,079 1,386,998 1,754,809 2,113,064 5,771,508
Total cost 8,177,417 8,239,472 8,510,603 9,009,044 32,443,516
Budget impact savings
−70,154 −117,203 −150,671 −185,595 −495,812
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total economic impact was estimated to be €107.92 million, 
€109.03 million, €112.79 million, and €119.48 million for 
2015, 2016, 2017, and 2018, respectively (Table 5). Overall, 
the total budget savings for Spain were expected to be €6.01 
million over the next 4 years (Tables 5 and 6). 
Results of the region-specific analysis vary widely. In the 
current scenario, the total economic impact was expected to 
be €65.49 million, €55.58 million, €30.45 million, €63.30 
million, and €32.94 million in Andalusia, Catalonia, Gali-
cia, Madrid, and Valencia, respectively, for the time period 
of 2015–2018 (Table 5). The economic impact of treating 
COPD was reduced in all Spanish regions with the introduc-
tion of Spiromax, alternative scenario, over the time period 
of 2015–2018. Thus, total costs were estimated to be €64.59 
million for Andalusia, €54.84 million for Catalonia, €29.98 
million for Galicia, €62.54 million for Madrid, and €32.44 
million for Valencia (Tables 5 and 6).
The comparison between the current scenario and the 
alternative scenario led to savings in all 5 Spanish regions. 
Total savings during the time period of 2015–2018 were 
estimated to be €902,133, €740,520, €464,281, €748,996, 
and €495,812 for Andalusia, Catalonia, Galicia, Madrid, 
and Valencia, respectively. Results were obtained through 
the reduction of health care resources, especially fewer days 
of hospital stay and avoided PC visits and emergency room 
visits (Table 6), the reduction in PC visits related to problems 
with the inhaler device being more important. 
Finally, the univariate deterministic sensitivity analysis 
confirmed the robustness of the model. Variations in the most 
sensitive parameters, such as COPD severity or the adher-
ence rate, do not lead to significant changes in the results 
of the analysis, since in all cases savings were obtained for 
both Spain and the 5 regions. In addition, when changing 
the age of the population considered, savings were obtained 
with the alternative scenario compared with the current one. 
Thus, the savings obtained ranged between €9.4 million and 
€606,641 for Spain and €1.7 million and €50,077 for the 5 
Spanish regions (Table 7). 
Table 6 Specific results: savings due to reduction of health care resource utilization in EUR 2015 (€)
Regions and savings in Euros (€) Year
2015 2016 2017 2018 Present value
Spain
Savings due to fewer days of hospital stay (€) −69,700 −116,795 −150,586 −186,024 −495,274
Savings due to fewer emergency room visits (€) −18,534 −31,057 −40,043 −49,466 −131,699
Savings due to avoided PC visits (€) −757,037 −1,268,563 −1,635,580 −2,020,488 −5,379,375
Total savings in Spain (€) −845,270 −1,416,415 −1,826,209 −2,255,979 −6,006,348
Andalusia
Savings due to fewer days of hospital stay (€) −12,447 −20,984 −27,218 −33,816 −89,421
Savings due to fewer emergency room visits (€) −2,096 −3,534 −4,584 −5,696 −15,062
Savings due to avoided PC visits (€) −111,025 −187,184 −242,784 −301,643 −797,650
Total savings in Andalusia (€) −125,567 −211,703 −274,586 −341,155 −902,133
Catalonia
Savings due to fewer days of hospital stay (€) −11,656 −19,400 −24,853 −30,518 −81,846
Savings due to fewer emergency room visits (€) −2,629 −4,375 −5,605 −6,882 −18,457
Savings due to avoided PC visits (€) −91,174 −151,751 −194,407 −238,722 −640,217
Total savings in Catalonia (€) −105,459 −175,526 −224,865 −276,122 −740,520
Galicia
Savings due to fewer days of hospital stay (€) −4,453 −7,464 −9,624 −11,887 −31,649
Savings due to fewer emergency room visits (€) −1,634 −2,738 −3,531 −4,361 −11,611
Savings due to avoided PC visits (€) −59,238 −99,287 −128,029 −158,127 −421,021
Total savings in Galicia (€) −65,324 −109,489 −141,184 −174,375 −464,281
Madrid
Savings due to fewer days of hospital stay (€) −10,909 −18,256 −23,507 −29,005 −77,334
Savings due to fewer emergency room visits (€) −3,143 −5,260 −6,773 −8,356 −22,281
Savings due to avoided PC visits (€) −91,605 −153,296 −197,390 −243,553 −649,381
Total savings in Madrid (€) −105,657 −176,812 −227,670 −280,914 −748,996
Valencia
Savings due to fewer days of hospital stay (€) −3,129 −5,227 −6,720 −8,277 −22,113
Savings due to fewer emergency room visits (€) −1,186 −1,981 −2,547 −3,137 −8,380
Savings due to avoided PC visits (€) −65,839 −109,995 −141,405 −174,181 −465,319
Total savings in Valencia (€) −70,154 −117,203 −150,671 −185,595 −495,812
Abbreviation: PC, primary care.
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Discussion
This study compared the costs of budesonide/formoterol FDC 
delivered by two different inhalation devices, Spiromax and 
Turbuhaler, to estimate the budget impact for the treatment 
of COPD in Spain and the 5 regions. Results of the budget 
impact analysis suggest that the increasing use of Spiromax 
would result in a 4-year budget savings for the Spanish NHS 
of €6.01 million at the national level. This model is also use-
ful for analyzing treatment cost at the regional level. Results 
suggest that savings summed up to €902,133, €740,520, 
€464,281, €748,996, and €495,812 for Andalusia, Catalo-
nia, Galicia, Madrid, and Valencia, respectively. 
These inhalation devices were also compared in other 
studies from different countries. Lewis et al38 conducted an 
assessment to determine the budget impact of using Spiromax 
instead of Turbuhaler to manage COPD in adult patients in 
the UK. They also analyzed the potential cost–benefit of the 
improved inhalation technique. In the Lewis et al study, the 
model predicted total drug cost savings of £36.09 million 
and further savings of £3.5 million due to improvement in 
inhalation technique. This assessment was been carried out by 
Torvinen et al39 on the Italian COPD population. Their model 
also anticipated a total drug cost savings of €53.66 million 
and additional savings of €4.12 million because of the pro-
gression in inhalation technique. Regarding other inhalation 
devices, Nicolai et al40 assessed the potential economic impact 
of introducing an inhaler with improved features compared to 
Spiriva® Handihaler® to treat COPD in the UK. The potential 
budgetary impact achieved by using the new inhaler instead of 
Handihaler is calculated as €104.91 per patient and €16.69 
million for the UK COPD population per year.
Adherence to inhaled drugs plays an important role in 
the management of COPD. Dealing with this chronic disease 
remains complex due to several problems such as the chronic-
ity of the disease, the use of multiple medications, the periods 
of symptom remission, comorbidities that limit the movement 
such as arthritis and osteoarthritis, and the lack of adherence 
related to the inhalation technique. Inhaled medication is 
typically prescribed in a maintenance therapy using FDCs, 
considering that single-inhaler combination regimens provide 
improved symptom control and slow down the progression 
of the disease.41,42 Although current prescription guidelines 
contribute to improve the quality of life of COPD patients, it 
was reported that up to 85% of the patients use their inhaler 
ineffectively, and this was associated with low medication 
adherence.41,43,44
Our estimates suggest that the introduction of Spiromax 
could result in savings by reducing health care resource T
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 utilization related to suboptimal medication adherence.45,46 
This new inhalation device helps to reduce common utiliza-
tion errors such as dose preparation errors, adequate flow 
rates, or even environmental conditions that might limit the 
delivery of the drug directly to the lungs, which would be 
closer to patients’ real-life situations.46
In addition, the current model can obtain region-specific 
results, which suggest that the highest populated regions 
correspond to those with greater savings for the health care 
budget. Andalusia would be best off, followed by Madrid 
and Catalonia. Indeed, these regions were expected to obtain 
higher savings if adherence improves in the patients diagnosed 
with COPD. It was also explored that the breakdown of overall 
savings and the savings due to avoided PC visits has shown 
to yield significant monetary savings. COPD is mostly found 
in a population older than 40 years, and the chronicity of the 
disease makes it relevant to focus effort in new strategies to 
solve the current problems of suboptimal adherence.43,47
Limitations
There were limitations to the BIM. Real-world clinical data 
were not collected for certain variables. When clinical data 
were not available, we used data from the literature. Due to 
differences in study population, geographic area, patients’ 
health status, and additional factors, some input variables 
may not be generalizable to all 5 regions. Moreover, the 
first assumption in the model was a growing market share 
of DuoResp Spiromax along with a reduction of Symbicort 
Turbuhaler and Rilast Turbuhaler utilization. Nevertheless, 
the estimate of the budget impact under this scenario may not 
predict the real-world changes. Furthermore, other formulae 
prescriptions different from budesonide/formoterol were not 
included, which could be an alternative for DuoResp Spi-
romax. Regarding the study results, it was found that gains 
in adherence generated savings for the health care budgets. 
Although these amounts could be considered conservative, 
they are adjusted only to be related with inhalation technique 
problems, and not with the whole adherence problem, which 
is linked with many factors.41,44
It is worth mentioning that difficulties in the use of 
inhaler devices were exacerbated in elderly patients, whose 
reduced inhalation effort leads to a poor drug release.48 A 
greater impact on the COPD economic budget was expected 
because of the aging population in Spain. Furthermore, it 
was also observed that underdiagnosis is a current problem 
in Spain, with up to 73% of COPD potential population 
remain unaware of their health status.45 Thus, COPD health 
care expenditure could be even higher since a low proportion 
of these patients was actually treated. 
Conclusion
The results from this analysis suggest that the introduction 
of DuoResp Spiromax would result in a €6.01 million 
decrease in Spain’s overall budget in the period 2015–2018 
associated with a lower health care resource utilization costs. 
Region-specific data resulted in savings in 5 Spanish regions 
of study which sum up to €902,133, €740,520, €464,281, 
€748,996, and €495,812 for Andalusia, Catalonia, Gali-
cia, Madrid, and Valencia, respectively. COPD treatment 
regimens that increase the probability of higher medication 
adherence rates would be expected to contribute to improved 
disease management and to have an impact on the utilization 
of health care resources.
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